A New Perspective on Nonprescription Statins: An Opportunity for Patient Education and Involvement

American Journal of Cardiology

Volumn 100, Issue 5, 2007, Pages 907-910

  Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NON PRESCRIPTION DRUG;

ARTICLE; AWARENESS; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PATIENT EDUCATION; PATIENT PARTICIPATION; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL;

EID: 34547954921     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.009     Document Type: Note

References (25)

1. Foot D.K., Lewis R.P., Pearson T.A., and Beller G.A. Demographics and cardiology 1950-2050. J Am Coll Cardiol 35 suppl (2000) 66B-80B
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
3. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J., National Heart, Lung, and and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
4. Ford E.S., Giles W.H., and Mokdad A.H. The distribution of 10-year risk for coronary heart disease among U.S. adults: findings from the national health and nutrition examination survey III. J Am Coll Cardiol 43 (2004) 1791-1796
5. Wong N.D., Lopez V., Tang S., and Williams G.R. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 98 (2006) 204-208
6. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century (2001), Institute of Medicine, Washington, DC
7. Ong K.L., Cheung B.M., Man Y.B., Lau C.P., and Lam K.S. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49 (2007) 69-75
8. Schoenborn C.A., Adams P.F., Barnes P.M., Vickerie J.L., and Schiller J.S. Health behaviors of adults: United States, 1999-2001. Vital Health Stat 219 (2004) 1-79
9. Smith R.A., Saslow D., Sawyer K.A., Burke W., Costanza M.E., Evans W.P., Foster R.S., Hendrick E., Eyre H.J., Sener S., and American Cancer Society High-Risk Work Group; American Cancer Society Screening Older Women Work Group; American Cancer Society Mammography Work Group; American Cancer Society Physical Examination Work Group; American Cancer Society New Technologies Work Group; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 53 (2003) 141-169
10. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3419
11. Joint Meeting of the Nonprescription Drugs Advisory Committee, Endocrinologic & Metabolic Drugs Advisory Committee, January 13-14, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4086M1.htm. Accessed June 4, 2007.
12. Lauer M.S. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 346 (2002) 1468-1474
13. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
14. Downs J.R., Clearfield M., Tyroler H.A., Whitney E.J., Kruyer W., Langendorfer A., Zagrebelsky V., Weis S., Shapiro D.R., Beere P.A., and Gotto A.M. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 87 (2001) 1074-1079
15. Strom B.L. Statins and over-the-counter availability. N Engl J Med 352 (2005) 1403-1405
16. Choudry N., and Avorn J. Over-the-counter statins. Ann Intern Med 142 (2005) 910-913
17. Gotto A. Over-the-counter statins and cardiovascular disease prevention: perspectives, challenges, and opportunities. Clin Pharmacol Ther 78 (2005) 213-217
18. Davidoff F. Primary prevention with over-the-counter statins: a cautionary tale. Clin Pharmacol Ther 78 (2005) 218-220
19. Barter P.J., and Rye K.A. The argument against the appropriateness of over-the-counter statins. Circulation 114 (2006) 1315-1320
20. Gotto A.M. Is it appropriate to make statins available over the counter?. Circulation 114 (2006) 1310-1314
21. Melin J.M., Struble W.E., Tipping R.W., Reynolds J.M., Vassil T.C., Levy S.J., Petrohoy T.M., Midgette P., Hemwall E.L., Levine J.G., and Irvin J.D. A consumer use study of over-the-counter lovastatin (CUSTOM). Am J Cardiol 94 (2004) 1243-1248
22. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., and Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
23. Brass E.P., Allen S.E., and Melin J.M. Potential impact on cardiovascular public health of over-the-counter statin availability. Am J Cardiol 97 (2006) 851-856
24. Law M., and Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 97 suppl (2006) 52C-60C
25. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., Nakaya N., Nishimoto S., Muranaka M., Yamamoto A., et al., MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368 (2006) 1155-1163